Sterile Water

Water


B. Braun Medical Inc.
Human Prescription Drug
NDC 0264-7850
Sterile Water also known as Water is a human prescription drug labeled by 'B. Braun Medical Inc.'. National Drug Code (NDC) number for Sterile Water is 0264-7850. This drug is available in dosage form of Injection. The names of the active, medicinal ingredients in Sterile Water drug includes Water - 1 mL/mL . The currest status of Sterile Water drug is Active.

Drug Information:

Drug NDC: 0264-7850
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Sterile Water
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Water
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: B. Braun Medical Inc.
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Injection
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:WATER - 1 mL/mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:INTRAVENOUS
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: NDA
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 24 Feb, 1988
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 20 Jan, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: NDA019633
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:B. Braun Medical Inc.
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:059QF0KO0R
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
0264-7850-0012 CONTAINER in 1 CASE (0264-7850-00) / 1000 mL in 1 CONTAINER24 Feb, 1988N/ANo
0264-7850-1024 CONTAINER in 1 CASE (0264-7850-10) / 500 mL in 1 CONTAINER24 Feb, 1988N/ANo
0264-7850-2024 CONTAINER in 1 CASE (0264-7850-20) / 250 mL in 1 CONTAINER24 Feb, 1988N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Product Elements:

Sterile water water water water

Indications and Usage:

Indications and usage sterile water for injection usp is indicated for use in adults and pediatric patients as a diluent or solvent in the aseptic preparation of parenteral solutions or as a vehicle for drug administration.

Warnings:

Warnings hypotonic and hemolytic. do not inject until made approximately isotonic by addition of an appropriate solute, due to the possibility of hemolysis. the administration of intravenous solutions can cause fluid and/or solute overload resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema. the risk of dilutional states is inversely proportional to the electrolyte concentration. warning: this product contains aluminum that may be toxic. aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum. research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central
nervous system and bone toxicity. tissue loading may occur at even lower rates of administration.

General Precautions:

General to minimize the risk of possible incompatibilities arising from the mixing of additives that may be prescribed, the final infusate should be inspected for cloudiness or precipitation immediately after mixing, prior to administration and periodically during administration. do not use plastic containers in series connection. if administration is controlled by a pumping device, care must be taken to discontinue pumping action before the container runs dry or air embolism may result. if administration is not controlled by a pumping device, refrain from applying excessive pressure (>300mmhg) causing distortion to the container such as wringing or twisting. such handling could result in breakage of the container. this solution is intended for intravenous administration using sterile equipment. it is recommended that intravenous administration apparatus be replaced at least once every 24 hours. use only if solution is clear and container and seals are intact. the drug product contains
no more than 25 mcg/l of aluminum.

Dosage and Administration:

Dosage and administration this solution is for intravenous use only. do not inject until made approximately isotonic by addition of appropriate solute. the dosage and administration of sterile water for injection usp is dependent upon the recommended dosage and administration of the solute used. fluid administration should be based on calculated maintenance or replacement fluid requirements for each patient. some additives may be incompatible. consult with pharmacist. when introducing additives, use aseptic techniques. mix thoroughly. do not store. parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

Contraindications:

Contraindications none known.

Adverse Reactions:

Adverse reactions refer to the package insert of the solute used. reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia. the physician should also be alert to the possibility of adverse reactions to drug additives. prescribing information for drug additives to be administered in this manner should be consulted. if an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.

Use in Pregnancy:

Usage in pregnancy refer to the package insert of the solute used.

Pediatric Use:

Pediatric use refer to the package insert of the solute used. see warnings section regarding aluminum.

Geriatric Use:

Geriatric use refer to the package insert of the solute used. see warnings section regarding aluminum.

Overdosage:

Overdosage overdosage (hypotonic expansion) is a function of an increase in fluid intake over fluid output, and occurs when the increase in the volume of body fluids is due to water alone. overdosage may occur in patients who receive large quantities of electrolyte-free water to replace abnormal excessive fluid losses, in patients whose renal tolerance to water loads is exceeded, or in patients who retain water postoperatively in response to stress. manifestations of water intoxication are behavioral changes (confusion, apathy, disorientation and attendant hyponatremia), central nervous system disturbances (weakness, muscle twitching, headaches, nausea, vomiting, convulsions) and weight gain. treatment consists of withholding fluids until excessive water is excreted. in severe hyponatremia it may be necessary to cautiously administer hypertonic saline to increase extracellular osmotic pressure and excretion of excess water by the kidneys.

Description:

Description sterile water for injection usp is a clear, colorless, odorless liquid. it is sterile, hypotonic, nonpyrogenic, and contains no bacteriostatic or antimicrobial agents. sterile water for injection usp is a diluent or solvent suitable for intravascular injection after first having been made approximately isotonic by the addition of suitable solute. ph: 5.5 (5.0–7.0) not made with natural rubber latex, pvc or dehp. the plastic container is made from a multilayered film specifically developed for parenteral drugs. it contains no plasticizers and exhibits virtually no leachables. the solution contact layer is a rubberized copolymer of ethylene and propylene. the container is nontoxic and biologically inert. the container-solution unit is a closed system and is not dependent upon entry of external air during administration. the container is overwrapped to provide protection from the physical environment and to provide an additional moisture barrier when necessary. addition of medication should be accomplished using complete aseptic technique. the closure system has two ports; the one for the administration set has a tamper evident plastic protector and the other is a medication addition site. refer to the directions for use of the container.

Clinical Pharmacology:

Clinical pharmacology sterile water for injection usp is used as a diluent or solvent for other parenteral drugs. as such, sterile water for injection usp contributes to the water for hydration when provided in parenteral drug and fluid therapy, after the introduction of suitable additives and/or mixture with suitable solutes to approximate isotonicity.

Carcinogenesis and Mutagenesis and Impairment of Fertility:

Carcinogenesis, mutagenesis, impairment of fertility refer to the package insert of the solute used.

How Supplied:

How supplied sterile water for injection usp is supplied sterile and nonpyrogenic in excel ® containers. the 1000 ml containers are packaged 12 per case; the 500 ml and 250 ml containers are packaged 24 per case. ndc ref size sterile water for injection usp (canada din 01927930) 0264-7850-00 l8500 1000 ml 0264-7850-10 l8501-01 500 ml 0264-7850-20 l8502 250 ml exposure of pharmaceutical products to heat should be minimized. avoid excessive heat. protect from freezing. it is recommended that the product be stored at room temperature (25°c); however, brief exposure up to 40°c does not adversely affect the product. storage in automated dispensing machines: brief exposure up to 2 weeks to ultraviolet or fluorescent light does not adversely affect the product labeling legibility; prolonged exposure can cause fading of the red label. rotate stock frequently.

Spl Patient Package Insert:

Directions for use of excel® container warning: hypotonic and hemolytic. do not inject until made approximately isotonic by addition of appropriate solute. caution: do not use plastic containers in series connection. to open tear overwrap down at notch and remove solution container. check for minute leaks by squeezing solution container firmly. if leaks are found, discard solution as sterility may be impaired. if supplemental medication is desired, follow directions below before preparing for administration. note : before use, perform the following checks: inspect each container. read the label. ensure solution is the one ordered and is within the expiration date. invert container and carefully inspect the solution in good light for cloudiness, haze, or particulate matter. any container which is suspect should not be used. use only if solution is clear and container and seals are intact. preparation for administration remove plastic protector from sterile set port at bottom of conta
iner. attach administration set. refer to complete directions accompanying set. to add medication warning: some additives may be incompatible. to add medication before solution administration prepare medication site. using syringe with 18–22 gauge needle, puncture medication port and inner diaphragm and inject. squeeze and tap ports while ports are upright and mix solution and medication thoroughly. to add medication during solution administration close clamp on the set. prepare medication site. using syringe with 18–22 gauge needle of appropriate length (at least 5/8 inch), puncture resealable medication port and inner diaphragm and inject. remove container from iv pole and/or turn to an upright position. evacuate both ports by tapping and squeezing them while container is in the upright position. mix solution and medication thoroughly. return container to in use position and continue administration.

Package Label Principal Display Panel:

Principal display panel - 1000 ml container label sterile water for injection usp warning: hypotonic and hemolytic. do not inject until made approximately isotonic by addition of appropriate solute. y94-003-264 ld-271-2 ref l8500 ndc 0264-7850-00 din 01927930 1000 ml excel ® container no antimicrobial or other substance has been added. ph: 5.5 (5.0-7.0) sterile, nonpyrogenic. single dose container. do not use in series connection. for intravenous use only. use only if solution is clear and container and seals are intact. warnings: some additives may be incompatible. consult with pharmacist. when introducing additives, use aseptic techniques. mix thoroughly. do not store. recommended storage: room temperature (25°c). avoid excessive heat. protect from freezing. see package insert. do not remove overwrap until ready for use. after removing the overwrap, check for minute leaks by squeezing container firmly. if leaks are found, discard solution as sterility may be impaired. not made with natural rubber latex, pvc or dehp. rx only excel is a registered trademark of b. braun medical inc. b. braun medical inc. bethlehem, pa 18018-3524 usa 1-800-227-2862 www.bbraun.com in canada, distributed by: b. braun of canada, ltd. scarborough, ontario m1h 2w4 y94-003-263 ld-131-3 exp lot recycle 7 1000 ml container label l8500

Principal display panel - 500 ml sterile water for injection usp warning: hypotonic and hemolytic. do not inject until made approximately isotonic by addition of appropriate solute. y94-003-342 ld-272-3 ref l8501-01 ndc 0264-7850-10 din 01927930 500 ml excel ® container no antimicrobial or other substance has been added. ph: 5.5 (5.0-7.0) sterile, nonpyrogenic. single dose container. do not use in series connection. for intravenous use only. use only if solution is clear and container and seals are intact. warnings: some additives may be incompatible. consult with pharmacist. when introducing additives, use aseptic techniques. mix thoroughly. do not store. recommended storage: room temperature (25°c). avoid excessive heat. protect from freezing. see package insert. do not remove overwrap until ready for use. after removing the overwrap, check for minute leaks by squeezing container firmly. if leaks are found, discard solution as sterility may be impaired. not made with natural rubber latex, pvc or dehp. rx only excel is a registered trademark of b. braun medical inc. b. braun medical inc. bethlehem, pa 18018-3524 usa 1-800-227-2862 www.bbraun.com in canada, distributed by: b. braun of canada, ltd. scarborough, ontario m1h 2w4 y94-003-265 ld-130-3 exp lot recycle 7 500 ml container label

Principal display panel - 250 ml sterile water for injection usp warning: hypotonic and hemolytic. do not inject until made approximately isotonic by addition of appropriate solute. y94-003-214 ld-273-2 ref l8502 ndc 0264-7850-20 din 01927930 250 ml excel ® container no antimicrobial or other substance has been added. ph: 5.5 (5.0-7.0) sterile, nonpyrogenic. single dose container. do not use in series connection. for intravenous use only. use only if solution is clear and container and seals are intact. warnings: some additives may be incompatible. consult with pharmacist. when introducing additives, use aseptic techniques. mix thoroughly. do not store. recommended storage: room temperature (25°c). avoid excessive heat. protect from freezing. see package insert. do not remove overwrap until ready for use. after removing the overwrap, check for minute leaks by squeezing container firmly. if leaks are found, discard solution as sterility may be impaired. not made with natural rubber latex, pvc or dehp. rx only excel is a registered trademark of b. braun medical inc. b. braun medical inc. bethlehem, pa 18018-3524 usa 1-800-227-2862 www.bbraun.com in canada, distributed by: b. braun of canada, ltd. scarborough, ontario m1h 2w4 y94-003-213 ld-129-3 exp lot recycle 7 250 ml container label l8502


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.